ArticleBlood2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02290951 (An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.Annals of hematology · 2026Pooled it
- CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.Journal of hematology & oncology · 2026Trial
- Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.CPT: pharmacometrics & systems pharmacology · 2026Trial
- Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.Journal of hematology & oncology · 2026Review
- Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.Cells · 2026Review
- Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.Biomarker research · 2026Review
- Clinical Outcomes and Exploratory Longitudinal CTL/Vβ Repertoire Remodeling in Patients with Relapsed or Refractory Large B-Cell Lymphoma and Follicular Lymphoma Treated with Epcoritamab.International journal of molecular sciences · 2026Article
- CD20 × CD3 Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas: Current Evidence, Therapeutic Integration, and Future Directions.Medicina (Kaunas, Lithuania) · 2026Review
- Article
- Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.HemaSphere · 2026Article
- Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.Cells · 2026Review
- Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.Blood advances · 2026Article
- Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.Frontiers in immunology · 2026Review
- Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.Hematology. American Society of Hematology. Education Program · 2025Article
- Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy.Cancers · 2025Review
- Advances in T-Cell-Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies.Cancer research and treatment · 2025Review
- Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.Journal of clinical medicine · 2025Review
- Review
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractPatients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified post-CAR-T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR-Ts. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression. The primary end point was objective response rate (ORR) by independent central review. The median number of prior lines of therapy was 3 (range, 2-9), 71.7% were refractory to CAR-Ts, and 48.3% relapsed within 90 days of CAR-T therapy. After a median follow-up of 16.2 months, ORR and complete response (CR) rate were 48.3% and 31.7%, respectively. Responses were similar across prior CAR-T products and time to relapse on CAR-T therapy. Median duration of response was 14.8 months and median duration of CR was not reached. Median progression-free survival and overall survival were 4.8 and 10.2 months, respectively. The most common treatment-emergent adverse event was cytokine release syndrome (48.3%; no grade ≥3 events). No cases of immune effector cell-associated neurotoxicity syndrome were reported. Grade ≥3 infections occurred in 12 patients (20.0%), 2 of which were COVID-19. Odronextamab monotherapy demonstrated encouraging efficacy and generally manageable safety, supporting its potential as an off-the-shelf option for patients after CAR-T therapy. This trial was registered at www.clinicaltrials.gov as #NCT02290951.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.